Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Caterina Vaghi
Observed name:
C. Vaghi
Institutions:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
Vall d'Hebron Hospital Universitari,
Vall d'Hebron Institute of Oncology
Observed institutions:
University of Milan,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
Vall d'Hebron Hospital Universitari,
Vall d'Hebron Institute of Oncology
ORCID:
0000-0001-5023-3521
Observed ORCID:
0000-0001-5023-3521
OpenAlex ID:
A5006536616
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
2019
·
Andrea Sartore-Bianchi
, Alessio Amatu
, et al.
·
The Oncologist
·
182
PDF
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
2024
·
Javier Ros
, Caterina Vaghi
, et al.
·
International Journal of Molecular Sciences
·
62
PDF
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
2021
·
Giorgio Patelli
, Caterina Vaghi
, et al.
·
Targeted Oncology
·
43
PDF
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
2022
·
Caterina Vaghi
, Gianluca Mauri
, et al.
·
Cancer Treatment Reviews
·
30
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies
2025
·
Caterina Vaghi
, Federica Tosi
, et al.
·
Drugs
·
16
PDF
Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer
2026
·
Clara Salva de Torres
, Evelyn Elias
, et al.
·
Cancer Treatment Reviews
·
10
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy
2024
·
Nadia Saoudi González
, Paola Valeria Marchese
, et al.
·
Expert Opinion on Investigational Drugs
·
9
Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients
2026
·
Patricia Garcia Pastor
, Nadia Saoudi González
, et al.
·
Genes
·
4
PDF
446P Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study
2021
·
A. Amatu
, S. Ghezzi
, et al.
·
Annals of Oncology
·
4
Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors
2026
·
J. Ros
, M.C. de Grandis
, et al.
·
ESMO Open
·
3
728MO Predictive value of low-frequency resistance mutations and relative mutant allele frequencies (rMAFs) in anti-EGFR rechallenge for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
2025
·
P. Mascaró Baselga
, F. Salvà Ballabrera
, et al.
·
Annals of Oncology
·
3
Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
2021
·
Giorgio Patelli
, Caterina Vaghi
, et al.
·
Targeted Oncology
·
2
PDF
21P Advancing tertiary lymphoid structure assessment in metastatic colorectal cancer with multiplex immunohistochemistry and digital pathology
2025
·
G. Serna
, C. Vaghi
, et al.
·
Immuno-Oncology Technology
·
1
42P Real-world outcomes of anti-EGFR rechallenge in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
2025
·
P. Mascaró Baselga
, F. Salvà Ballabrera
, et al.
·
Annals of Oncology
·
1
PDF
121P Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
2024
·
C. Vaghi
, F.J. Ros Montana
, et al.
·
Annals of Oncology
·
1
PDF
Comprehensive characterisation of patients with colorectal cancer and permanently liver-limited disease
2026
·
F. Salva
, I. Baraibar
, et al.
·
ESMO Gastrointestinal Oncology
PDF
Relative Mutant Allele Frequency Role in ctDNA-Guided Anti–Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer
2026
·
Jesús Yaringaño
, Patricia García Pastor
, et al.
·
JCO Precision Oncology
100P Determinants of response to atezolizumab–bevacizumab (atezo–bev) in metastatic colorectal cancer (mCRC): Insights from the Motricolor CT3 trial
2026
·
C. Vaghi
, F.J. Ros Montana
, et al.
·
Annals of Oncology
PDF
Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2 -Amplified Metastatic Colorectal Cancer
2026
·
Patricia Garcia-Pastor
, Javier Ros
, et al.
·
JCO Precision Oncology
New prognostic and predictive scoring systems for colorectal cancer liver metastases
2026
·
F. Salvà
, S. Pérez Fernandez
, et al.
·
ESMO Open
858P Exploring antigen presentation (AP) and Wnt/β-Catenin (Wnt) pathway alterations as predictors of immune checkpoint inhibitors (ICI) resistance in patients (pts) with microsatellite instable (MSI) and microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
2025
·
C. Salva de Torres
, F.J. Ros Montana
, et al.
·
Annals of Oncology
901eP Tertiary lymphoid structures (TLSs) in metastatic colorectal cancer (mCRC) as potential biomarkers of response to immune checkpoint inhibitor (ICI)-based treatments
2025
·
C. Vaghi
, G. Serna
, et al.
·
Annals of Oncology
Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
2025
·
J. Ros
, V. Navarro
, et al.
·
ESMO Gastrointestinal Oncology
PDF
18P Combined analysis of plasmatic mutant allele fraction (pMAF) and RECISTv1.1 in MSI metastatic colorectal cancer (mCRC) treated with immune-checkpoint inhibitors (ICI)
2025
·
F.J. Ros Montana
, V. Navarro
, et al.
·
Annals of Oncology
PDF
69P Prognostic impact of weight loss on overall survival in metastatic colorectal cancer: A call for integrating nutritional interventions into oncological care
2025
·
A. Alcaraz
, L. Cabañas-Alite
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
29
Citation count:
371
H-index:
7
I10-index:
6
Year
Topic
Type